U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Recurrent Poorly Differentiated Thyroid Gland Carcinoma

MedGen UID:
1728704
•Concept ID:
C5420544
•
Neoplastic Process

Definition

The reemergence of poorly differentiated thyroid gland carcinoma after a period of remission. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRecurrent Poorly Differentiated Thyroid Gland Carcinoma

Professional guidelines

PubMed

Spanish consensus for the management of patients with anaplastic cell thyroid carcinoma.
Jiménez-Fonseca P, Gómez Saez JM, Santamaria Sandi J, Capdevila J, Navarro Gonzalez E, Zafon Llopis C, Ramón Y Cajal Asensio T, Riesco-Eizaguirre G, Grande E, Galofré JC
Clin Transl Oncol 2017 Jan;19(1):12-20. Epub 2016 Apr 5 doi: 10.1007/s12094-016-1506-0. PMID: 27048161
Spanish consensus for the management of patients with anaplastic cell thyroid carcinoma.
Gómez Sáez JM, Jiménez-Fonseca P, Santamaría Sandi J, Capdevila Castillón J, Navarro González E, Zafón Llopis C, Ramón Y Cajal Asensio T, Riesco Eizaguirre G, Grande Pulido E, Galofré Ferrater JC
Endocrinol Nutr 2015 Mar;62(3):e15-22. Epub 2015 Jan 9 doi: 10.1016/j.endonu.2014.11.006. PMID: 25583658
Management of carcinoma of the thyroid.
Block MA
Ann Surg 1977 Feb;185(2):133-44. doi: 10.1097/00000658-197702000-00001. PMID: 319768Free PMC Article

Recent clinical studies

Etiology

Thyroid Cancer: A Review.
Boucai L, Zafereo M, Cabanillas ME
JAMA 2024 Feb 6;331(5):425-435. doi: 10.1001/jama.2023.26348. PMID: 38319329
Follicular cell-derived thyroid cancer.
Dralle H, Machens A, Basa J, Fatourechi V, Franceschi S, Hay ID, Nikiforov YE, Pacini F, Pasieka JL, Sherman SI
Nat Rev Dis Primers 2015 Dec 10;1:15077. doi: 10.1038/nrdp.2015.77. PMID: 27188261
Poorly differentiated thyroid cancer.
Patel KN, Shaha AR
Curr Opin Otolaryngol Head Neck Surg 2014 Apr;22(2):121-6. doi: 10.1097/MOO.0000000000000037. PMID: 24492853
An update on molecular biology of thyroid cancers.
Omur O, Baran Y
Crit Rev Oncol Hematol 2014 Jun;90(3):233-52. Epub 2013 Dec 18 doi: 10.1016/j.critrevonc.2013.12.007. PMID: 24405857
Recurrent differentiated thyroid cancer.
Shaha AR
Endocr Pract 2012 Jul-Aug;18(4):600-3. doi: 10.4158/EP12047.CO. PMID: 22849875

Diagnosis

Thyroid Cancer: A Review.
Boucai L, Zafereo M, Cabanillas ME
JAMA 2024 Feb 6;331(5):425-435. doi: 10.1001/jama.2023.26348. PMID: 38319329
TERT promoter mutations in thyroid cancer.
Liu R, Xing M
Endocr Relat Cancer 2016 Mar;23(3):R143-55. Epub 2016 Jan 5 doi: 10.1530/ERC-15-0533. PMID: 26733501Free PMC Article
Follicular cell-derived thyroid cancer.
Dralle H, Machens A, Basa J, Fatourechi V, Franceschi S, Hay ID, Nikiforov YE, Pacini F, Pasieka JL, Sherman SI
Nat Rev Dis Primers 2015 Dec 10;1:15077. doi: 10.1038/nrdp.2015.77. PMID: 27188261
Poorly differentiated thyroid cancer.
Patel KN, Shaha AR
Curr Opin Otolaryngol Head Neck Surg 2014 Apr;22(2):121-6. doi: 10.1097/MOO.0000000000000037. PMID: 24492853
Recurrent differentiated thyroid cancer.
Shaha AR
Endocr Pract 2012 Jul-Aug;18(4):600-3. doi: 10.4158/EP12047.CO. PMID: 22849875

Therapy

Radioiodine adjuvant therapy in differentiated thyroid cancer: An update and reconsideration.
Sun YQ, Sun D, Zhang X, Zhang YQ, Lin YS
Front Endocrinol (Lausanne) 2022;13:994288. Epub 2022 Nov 30 doi: 10.3389/fendo.2022.994288. PMID: 36531486Free PMC Article
Advanced imaging and theranostics in thyroid cancer.
Roseland ME, Dewaraja YK, Wong KK
Curr Opin Endocrinol Diabetes Obes 2022 Oct 1;29(5):456-465. Epub 2022 Jul 2 doi: 10.1097/MED.0000000000000740. PMID: 36068937Free PMC Article
Follicular cell-derived thyroid cancer.
Dralle H, Machens A, Basa J, Fatourechi V, Franceschi S, Hay ID, Nikiforov YE, Pacini F, Pasieka JL, Sherman SI
Nat Rev Dis Primers 2015 Dec 10;1:15077. doi: 10.1038/nrdp.2015.77. PMID: 27188261
An update on molecular biology of thyroid cancers.
Omur O, Baran Y
Crit Rev Oncol Hematol 2014 Jun;90(3):233-52. Epub 2013 Dec 18 doi: 10.1016/j.critrevonc.2013.12.007. PMID: 24405857
Insular variant of poorly differentiated thyroid carcinoma.
Fat I, Kulaga M, Dodis R, Carling T, Theoharis C, Rennert NJ
Endocr Pract 2011 Jan-Feb;17(1):115-21. doi: 10.4158/EP09368.RA. PMID: 20634178

Prognosis

New Insights into Immune Cells and Immunotherapy for Thyroid Cancer.
Tao Y, Li P, Feng C, Cao Y
Immunol Invest 2023 Nov;52(8):1039-1064. Epub 2023 Nov 24 doi: 10.1080/08820139.2023.2268656. PMID: 37846977
TERT promoter mutations in thyroid cancer.
Liu R, Xing M
Endocr Relat Cancer 2016 Mar;23(3):R143-55. Epub 2016 Jan 5 doi: 10.1530/ERC-15-0533. PMID: 26733501Free PMC Article
Follicular cell-derived thyroid cancer.
Dralle H, Machens A, Basa J, Fatourechi V, Franceschi S, Hay ID, Nikiforov YE, Pacini F, Pasieka JL, Sherman SI
Nat Rev Dis Primers 2015 Dec 10;1:15077. doi: 10.1038/nrdp.2015.77. PMID: 27188261
When thyroid carcinoma goes bad: a morphological and molecular analysis.
Papp S, Asa SL
Head Neck Pathol 2015 Mar;9(1):16-23. Epub 2015 Mar 25 doi: 10.1007/s12105-015-0619-z. PMID: 25804379Free PMC Article
Recurrent differentiated thyroid cancer.
Shaha AR
Endocr Pract 2012 Jul-Aug;18(4):600-3. doi: 10.4158/EP12047.CO. PMID: 22849875

Clinical prediction guides

Thyroid Cancer: A Review.
Boucai L, Zafereo M, Cabanillas ME
JAMA 2024 Feb 6;331(5):425-435. doi: 10.1001/jama.2023.26348. PMID: 38319329
Prognostic of recurrence and survival in poorly differentiated thyroid cancer.
Hescot S, Al Ghuzlan A, Henry T, Sheikh-Alard H, Lamartina L, Borget I, Hadoux J, Baudin E, Dupuy C, Nikitski AV, Nikiforov YE, Schlumberger M, Nikiforova MN, Leboulleux S
Endocr Relat Cancer 2022 Nov 1;29(11):625-634. Epub 2022 Sep 30 doi: 10.1530/ERC-22-0151. PMID: 36040800
Value of thyroglobulin post hemithyroidectomy for cancer: a literature review.
Tourani SS, Fleming B, Gundara J
ANZ J Surg 2021 Apr;91(4):724-729. Epub 2020 Nov 26 doi: 10.1111/ans.16459. PMID: 33244886
PET imaging for thyroid cancers: Current status and future directions.
Giraudet AL, Taïeb D
Ann Endocrinol (Paris) 2017 Feb;78(1):38-42. Epub 2016 Dec 15 doi: 10.1016/j.ando.2016.10.002. PMID: 27989550
Prognostic value of vascular invasion in well-differentiated papillary thyroid carcinoma.
Wreesmann VB, Nixon IJ, Rivera M, Katabi N, Palmer F, Ganly I, Shaha AR, Tuttle RM, Shah JP, Patel SG, Ghossein RA
Thyroid 2015 May;25(5):503-8. Epub 2015 Mar 31 doi: 10.1089/thy.2015.0052. PMID: 25748079Free PMC Article

Recent systematic reviews

Prevalence of Differentiated High-Grade Thyroid Carcinoma Among Well-Differentiated Tumors: A Systematic Review and Meta-Analysis.
Poma AM, Macerola E, Ghossein RA, Tallini G, Basolo F
Thyroid 2024 Mar;34(3):314-323. doi: 10.1089/thy.2023.0350. PMID: 38115626Free PMC Article
Programmed Death-Ligand 1 (PD-L1) Is a Potential Biomarker of Disease-Free Survival in Papillary Thyroid Carcinoma: a Systematic Review and Meta-Analysis of PD-L1 Immunoexpression in Follicular Epithelial Derived Thyroid Carcinoma.
Girolami I, Pantanowitz L, Mete O, Brunelli M, Marletta S, Colato C, Trimboli P, Crescenzi A, Bongiovanni M, Barbareschi M, Eccher A
Endocr Pathol 2020 Sep;31(3):291-300. doi: 10.1007/s12022-020-09630-5. PMID: 32468210

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...